#USA #INOVIO #Plymouth Meeting #COVID-19 #DMAbs

INOVIO Announces Significant Results in COVID-19 DMAbs Trials

INOVIO Pharmaceuticals, a company known for its pioneering work in DNA medicines, has recently disclosed promising findings from its ongoing Phase 1 trial involving DNA-encoded monoclonal antibodies (DMAbs) aimed at combating COVID-19. This landmark study represents a significant advancement in the use of synthetic DNA technology in immunotherapy.

Trial Highlights

The trial's interim results have revealed that all participants who have reached 72 weeks maintained stable levels of DMAbs, signaling a robust and durable immune response. Out of 24 individuals, none developed anti-drug antibodies (ADA), a common issue seen with many gene-based antibody delivery systems. This finding is particularly noteworthy as it suggests a potential workaround for the challenges typically associated with traditional monoclonal antibody therapies, which can be hampered by the body’s immune response.

Moreover, the DMAbs were reported to be well-tolerated among participants. The most frequent side effects were mild local reactions at the injection site, such as pain and redness, with no serious adverse events linked to the treatment. These results underline the potential for DMAbs to offer both effectiveness and safety in therapeutic settings.

Collaborative Efforts

The trial is being conducted by The Wistar Institute in collaboration with INOVIO and AstraZeneca, in addition to clinical researchers from the University of Pennsylvania's Perelman School of Medicine. David B. Weiner, Ph.D., Executive Vice President of The Wistar Institute and the principal investigator, remarked, “This study provides the first clinical proof-of-concept that DNA-encoded monoclonal antibodies can be durably and tolerably expressed in humans.” He emphasized the implications of these findings, particularly the capacity of DMAb technology to potentially revolutionize treatment options for various diseases, including cancers and metabolic disorders.

Overcoming Traditional Challenges

One of the notable breakthroughs from this study is the demonstration that DMAbs can achieve sustained production of therapeutic antibodies without eliciting ADA — a major barrier in previous strategies utilizing gene-based vector systems like adeno-associated viruses. Dr. Pablo Tebas, a professor of Infectious Diseases at Penn and trial investigator, explained that their DNA-based method shows promise as a long-term treatment option due to its ability to maintain active antibodies for extended periods.

INOVIO's Chief Scientific Officer, Laurent Humeau, Ph.D., expressed enthusiasm about the potential applications of their DNA medicine technology, stating that it could pave the way for targeted therapies in diseases characterized by missing or defective proteins.

Next Steps

The consortium involved plans to present further interim results from this promising trial at several upcoming scientific conferences in 2025. A manuscript detailing these findings has already been submitted for peer review, signifying a push for transparency and shared knowledge within the scientific community regarding the clinical advancements being made.

The Phase 1 trial not only marks a vital step in the realm of COVID-19 treatment but also sets a precedent for the future application of DNA-encoded antibodies. The prospect of efficiently generating therapeutic proteins through direct delivery methods could fundamentally alter treatment landscapes across numerous medical disciplines.

Conclusion

As INOVIO continues to make strides in developing innovative therapeutic strategies, the results from this DMAb trial not only highlight their commitment to advancing healthcare but also the transformative potential of DNA medicine technology. The journey toward achieving long-lasting and effective treatments for infectious diseases like COVID-19 has taken a hopeful turn, signaling a new horizon in biotechnology and pharmaceutical research.